We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+25%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$55.8M
AUM Growth
+$9.14M
(+20%)
Cap. Flow
+$1.17M
Cap. Flow
% of AUM
2.09%
Top 10 Holdings %
Top 10 Hldgs %
49.65%
Holding
44
New
22
Increased
4
Reduced
7
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Baxter International
BAX
|
+$4.32M |
| 2 |
Guardant Health
GH
|
+$2.54M |
| 3 |
Viatris
VTRS
|
+$2.47M |
| 4 |
Centene
CNC
|
+$2.41M |
| 5 |
UnitedHealth
UNH
|
+$1.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$3.64M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.78M |
| 3 |
Insmed
INSM
|
+$2.78M |
| 4 |
PTC Therapeutics
PTCT
|
+$2.76M |
| 5 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$2.73M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.32% |
| 2 | Financials | 2.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Baxter International
BAX
$12.1B
| $4.36M | 7.82% |
+52,192
| New | +$4.32M |
|
2
BioMarin Pharmaceuticals
BMRN
$11.6B
| $2.86M | 5.12% |
33,781
-15,481
| -31% | -$1.17M |
|
|
3
Centene
CNC
$31.6B
| $2.79M | 5.01% |
+44,426
| New | +$2.41M |
|
|
4
Guardant Health
GH
$19.3B
| $2.75M | 4.93% |
+35,236
| New | +$2.54M |
|
|
5
Insmed
INSM
$22.7B
| $2.72M | 4.87% |
113,875
-136,709
| -55% | -$2.78M |
|
|
6
Viatris
VTRS
$20.5B
| $2.67M | 4.79% |
+132,855
| New | +$2.47M |
|
|
7
PTC Therapeutics
PTCT
$6.29B
| $2.66M | 4.77% |
55,408
-65,041
| -54% | -$2.76M |
|
8
Tandem Diabetes Care
TNDM
$1.18B
| $2.6M | 4.65% |
43,559
+24,564
| +129% | +$1.51M |
|
9
Bio-Rad Laboratories Class A
BIO
$8.47B
| $2.35M | 4.21% |
6,351
+713
| +13% | +$251K |
|
|
ARNA
10
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.94M | 3.48% |
42,688
+26,416
| +162% | +$1.25M |
|
|
11
UnitedHealth
UNH
$379B
| $1.89M | 3.38% |
+6,414
| New | +$1.68M |
|
12
Regeneron Pharmaceuticals
REGN
$69.9B
| $1.72M | 3.08% |
+4,584
| New | +$1.54M |
|
|
MYOK
13
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $1.68M | 3.01% |
23,023
-24,879
| -52% | -$1.51M |
|
14
AbbVie
ABBV
$454B
| $1.68M | 3% |
+18,921
| New | +$1.57M |
|
|
AERI
15
DELISTED
Aerie Pharmaceuticals
AERI
| $1.51M | 2.71% |
+62,507
| New | +$1.29M |
|
|
DERM
16
DELISTED
Dermira, Inc.
DERM
| $1.44M | 2.58% |
+81,127
| New | +$700K |
|
17
Exicure
XCUR
$11.2M
| $1.43M | 2.56% |
+3,333
| New | +$1.36M |
|
|
ESPR
18
DELISTED
Esperion Therapeutics
ESPR
| $1.36M | 2.44% |
+22,872
| New | +$1.03M |
|
19
Gilead Sciences
GILD
$162B
| $1.35M | 2.42% |
20,791
-32,695
| -61% | -$2.13M |
|
|
BMY.RT
20
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $1.25M | 2.24% |
+415,931
| New | +$1.08M |
|
|
MNTA
21
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $1.24M | 2.21% |
+62,585
| New | +$1M |
|
22
eHealth
EHTH
$43.2M
| $1.23M | 2.2% |
+15,004
| New | +$1.16M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $1.18M | 2.12% |
49,431
-100,868
| -67% | -$2.78M |
|
24
Twist Bioscience
TWST
$5.39B
| $1.14M | 2.05% |
54,334
+16,116
| +42% | +$377K |
|
|
VRAY
25
DELISTED
ViewRay, Inc.
VRAY
| $1.08M | 1.94% |
+256,205
| New | +$828K |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Asymmetry Capital Management held 44 positions worth $55.8M, up 20% from $46.7M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Asymmetry Capital Management's Q4 2019 filing shows 22 new, 4 increased, 7 reduced and 11 closed positions. Its largest new stake was Baxter International: 52,192 shares worth $4.36M. The largest sale was Global Blood Therapeutics, Inc., an estimated $3.64M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 91% a quarter earlier, followed by Financials.
- Asymmetry Capital Management's largest Q4 2019 buy was Baxter International: 52,192 shares worth $4.36M.
- Asymmetry Capital Management added most to Tandem Diabetes Care in Q4 2019, an estimated $1.51M increase.
- Asymmetry Capital Management's biggest Q4 2019 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $2.78M.
- Asymmetry Capital Management fully exited Global Blood Therapeutics, Inc. in Q4 2019, selling an estimated $3.64M.
- Asymmetry Capital Management's ten largest holdings make up 50% of its $55.8M portfolio in Q4 2019.
- Asymmetry Capital Management opened 22 new positions and closed 11 in Q4 2019.
- Asymmetry Capital Management's portfolio value rose 20% quarter-over-quarter to $55.8M.
Based on Asymmetry Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.